Ticker brief
EPRX EUPRAXIA PHARMACEUTICALS INC
Consumer, Non-cyclical · Biotechnology
last close
$6.87
1 day
-9.5%
14 days
-7.9%
mkt cap
·
signals 14d
13
authors 14d
5
crowd 14d
+0.1σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @VistaPResearch | C | · | 8 | +0.14 |
| @Gantosj | B | -2.45 | 2 | +0.45 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @OzmosiHealth | C | · | 1 | +0.15 |
| @PrismMarketView | C | · | 1 | +0.20 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @VistaPResearch | +0.00 | Briefly describes the disease targeted by Eupraxia; linked context is needed for significance. | +3.8% | tweet ↗ |
| 2026-10-15 | @PrismMarketView | +0.20 | Eupraxia reached its Phase 2b enrollment target with interim analysis due in December. | +1.5% | tweet ↗ |
| 2026-10-15 | @VistaPResearch | +0.30 | Eupraxia reports reaching the RESOLVE trial enrollment target for EP-104GI. | +1.5% | tweet ↗ |
| 2026-10-15 | @OzmosiHealth | +0.15 | Eupraxia reached its enrollment target for the RESOLVE trial. | +1.5% | tweet ↗ |
| 2026-10-15 | @Gantosj | +0.35 | Eupraxia's 60-patient Phase 2b interim analysis remains on track for December 2026. | +1.5% | tweet ↗ |
| 2026-10-15 | @Gantosj | +0.55 | Eupraxia reached its RESOLVE enrollment target with no sample-size adjustment required. | +1.5% | tweet ↗ |
| 2026-10-12 | @VistaPResearch | +0.05 | Eupraxia announces presentations at two named medical conferences on Oct. 9–14. | -6.1% | tweet ↗ |
| 2026-10-08 | @Quantumup1 | +0.40 | Cantor reiterated Overweight and a $19 target, citing undervaluation and Phase 2b upside. | -9.2% | tweet ↗ |
| 2026-10-07 | @VistaPResearch | +0.05 | Reports Eupraxia up 0.26% to $7.76; other cashtags are not part of the observation. | -11.7% | tweet ↗ |
| 2026-10-06 | @VistaPResearch | +0.15 | Reports EPRX up 1.36% to $7.85. | -11.2% | tweet ↗ |
| 2026-10-05 | @VistaPResearch | +0.30 | Reports EPRX up 8.01% to $7.82. | -11.4% | tweet ↗ |
| 2026-10-05 | @VistaPResearch | +0.20 | Reports only EPRX's 4.90% rise; trailing cashtags are unrelated topic tags. | -11.4% | tweet ↗ |
| 2026-10-05 | @VistaPResearch | +0.10 | Reports EPRX up 1.24% to $7.33. | -11.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.